BACKGROUND: Surgical management is currently the most common treatment offered for ruptured Achilles tendon; however, the length of hospital stay varies among hospitals. The objective of our study was to compare the costs associated with hospital stay and safety in 2 groups of patients undergoing surgical treatment of Achilles tendon ruptures. The first group of patients represented the surgical arm of a randomized clinical trial, the Multicentre Achilles Tendon Treatment Study (MATTS), and the second group comprised surgically treated patients not included in that trial (non-MATTS). METHODS: We performed an observational analytical retrospective chart review of all patients surgically treated for acute Achilles tendon ruptures at all Calgary-area hospitals over a 3-year period (October 2002-September 2005) who met our inclusion criteria. We determined the costs associated with hospital stay, complications and readmissions for all patients. RESULTS: A total of 282 patients met our inclusion criteria. Hospital admission costs of patients enrolled in the MATTS trial were less than those of non-MATTS patients treated at each of the 3 Calgary adult hospitals. Non-MATTS patients remained in hospital for 1-4 days in contrast to MATTS patients, who were typically admitted and discharged the day of surgery. The complication rate was similar in both groups (MATTS 9% v. non-MATTS 8%). There were no readmissions in the MATTS group and 2 in the non-MATTS group. Between October 2002 and September 2005, an additional $236,436 was spent on non-MATTS patients who underwent surgery for Achilles tendon rupture. CONCLUSION:Acute achilles tendon repair surgery is safe and less costly as an out-patient procedure.
RCT Entities:
BACKGROUND: Surgical management is currently the most common treatment offered for ruptured Achilles tendon; however, the length of hospital stay varies among hospitals. The objective of our study was to compare the costs associated with hospital stay and safety in 2 groups of patients undergoing surgical treatment of Achilles tendon ruptures. The first group of patients represented the surgical arm of a randomized clinical trial, the Multicentre Achilles Tendon Treatment Study (MATTS), and the second group comprised surgically treated patients not included in that trial (non-MATTS). METHODS: We performed an observational analytical retrospective chart review of all patients surgically treated for acute Achilles tendon ruptures at all Calgary-area hospitals over a 3-year period (October 2002-September 2005) who met our inclusion criteria. We determined the costs associated with hospital stay, complications and readmissions for all patients. RESULTS: A total of 282 patients met our inclusion criteria. Hospital admission costs of patients enrolled in the MATTS trial were less than those of non-MATTS patients treated at each of the 3 Calgary adult hospitals. Non-MATTS patients remained in hospital for 1-4 days in contrast to MATTS patients, who were typically admitted and discharged the day of surgery. The complication rate was similar in both groups (MATTS 9% v. non-MATTS 8%). There were no readmissions in the MATTS group and 2 in the non-MATTS group. Between October 2002 and September 2005, an additional $236,436 was spent on non-MATTS patients who underwent surgery for Achilles tendon rupture. CONCLUSION: Acute achilles tendon repair surgery is safe and less costly as an out-patient procedure.
Authors: Mohit Bhandari; Gordon H Guyatt; Farhan Siddiqui; Farrah Morrow; Jason Busse; Ross K Leighton; Sheila Sprague; Emil H Schemitsch Journal: Clin Orthop Relat Res Date: 2002-07 Impact factor: 4.176
Authors: Lasse J Lapidus; Stefan Rosfors; Sari Ponzer; Catharina Levander; Anders Elvin; Gerd Lärfars; Edin de Bri Journal: J Orthop Trauma Date: 2007-01 Impact factor: 2.512
Authors: M Tohidnezhad; D Varoga; C J Wruck; L O Brandenburg; A Seekamp; M Shakibaei; T T Sönmez; Thomas Pufe; S Lippross Journal: Histochem Cell Biol Date: 2011-04-08 Impact factor: 4.304
Authors: Benjamin Dallaudière; Marta Lempicki; Lionel Pesquer; Liliane Louedec; Pierre Marie Preux; Philippe Meyer; Vincent Hummel; Ahmed Larbi; Lydia Deschamps; Clement Journe; Agathe Hess; Alain Silvestre; Paul Sargos; Philippe Loriaut; Patrick Boyer; Elisabeth Schouman-Claeys; Jean Baptiste Michel; Jean Michel Serfaty Journal: Eur Radiol Date: 2013-06-26 Impact factor: 5.315
Authors: M R Carmont; C Heaver; A Pradhan; O Mei-Dan; K Gravare Silbernagel Journal: Knee Surg Sports Traumatol Arthrosc Date: 2013-02-02 Impact factor: 4.342
Authors: Benjamin Dallaudiere; Liliane Louedec; Marie Paule Jacob Lenet; Lionel Pesquer; Elvind Blaise; Anne Perozziello; Jean Baptiste Michel; Maryse Moinard; Philippe Meyer; Jean Michel Serfaty Journal: Muscles Ligaments Tendons J Date: 2015-07-03